Pegvisomant
- Evidence
- Approved drug evidence
- Class
- GH receptor antagonist
Pegvisomant belongs to the GH receptor antagonist class. This library groups it under hormones & metabolism. Its source category is FDA-approved.
At a glance
| Compound class | GH receptor antagonist |
|---|---|
| Associated brands | Somavert |
| Body system | Hormones & metabolism |
| Use or research focus | Acromegaly |
| Regulatory status | FDA-approved |
| Source evidence rating | Approved drug evidence |
How does Pegvisomant work?
Blocks GH receptor, lowers IGF-1.
The source catalog maps this mechanism to Pituitary, Liver. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
An approved medicine can still have contraindications, interactions, and serious adverse effects. The current prescribing label is the place to check product-specific warnings. A clinician should review your medical history and other medicines before treatment.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Pegvisomant?
Pegvisomant belongs to the GH receptor antagonist class. This library groups it under hormones & metabolism. Its source category is FDA-approved. Its recorded use or research focus is: Acromegaly.
Is Pegvisomant FDA-approved?
The catalog records: FDA-approved. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Where can I read the research?
The Citations tab contains 2 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for hormones & metabolism
Factual catalog fields and citation links are adapted from Superpower’s Pegvisomant guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Pegvisomant in the source dataset. Open a source to review its study design, population, limitations, and date.
View the original research guide